Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated December 12, 2025, reports a significant regulatory milestone for its respiratory syncytial virus (RSV) vaccine, Arexvy. The filing details a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding an expanded indication for the vaccine.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a regulatory update rather than a financial results report.
Material Changes and Developments
- Regulatory Approval: The CHMP has recommended expanding the indication of Arexvy to all adults aged 18 years and older in the European Union and European Economic Area.
- Previous Indication: Arexvy was previously approved for adults aged 60 and older, and those aged 50-59 with increased risk factors.
- Market Impact: If approved by the European Commission (expected in February 2026), the vaccine will be available to a significantly broader adult population, addressing a market where an average of 158,000 adults are hospitalized annually with RSV-related illness in the EU.
Guidance, Outlook, and Risks
Outlook: GSK anticipates a final decision from the European Commission in February 2026. The company is also pursuing expanded indications for Arexvy in other geographies, including the US and Japan.
Management Commentary: Sanjay Gurunathan, Head of Vaccines and Infectious Diseases R&D, stated that this opinion is a crucial step in increasing access to RSV prevention for broader adult populations in Europe.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements. Actual results may differ due to risks described in GSK's 2024 Annual Report on Form 20-F and Q3 2025 results. Additionally, the text notes that a protective immune response may not be elicited in all vaccinees.
Investor Verification Checklist
- Confirm the final approval date and specific terms of the European Commission's decision expected in February 2026.
- Monitor the status of expanded indication applications in the US and Japan.
- Review the "Risk Factors" section of the 2024 Form 20-F for detailed regulatory and commercial risks.
- Assess the potential revenue impact of expanding the addressable market from adults 60+ to all adults 18+ in the EU.